Rob Dillard

DocwireNews

Researchers reported updated results from a phase I trial of donor-derived CD7 chimeric antigen receptor (CAR) T cells for relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). The results were presented at the 2022 American Society of Clinical Oncology Annual Meeting.
This study, conducted by Jing Pan and colleagues, was comprised of 20 patients with prior stem cell transplantation (SCT). The population of interest all received CAR T cells from prior SCT donors, while patients without SCT history received CAR T cells from new donors who provided stem cells CAR T therapy, the researchers noted. The primary outcome of interest in this analysis was safety with efficacy secondary.
According to the results, 95% of patients responded and were followed for over 15 months. The short-term adverse events reported included grade 3 or higher cytokine release syndrome (10%) and grade 1-2 graft-versus-host disease (GVHD, 60%), which were all reversible, the researchers wrote. The objective response and complete remission rate were 95% and 85% following day 30 post-infusion, with one-year progressive-free survival (PFS) and overall survival (OS) rates observed at 51.6% (95% CI, 24.7-78.4%) and 72.5% (95% CI, 51.9-93.0%), respectively].
“Donor-derived CD7 CAR T cell therapy showed encouraging activity in treating r/r T-ALL. Relapse emerges as major issues impeding long-term outcomes. CD7-negative relapse was commonly observed under CAR T cell surveillance. Late onset GVHD and infections may occur and should be carefully managed,” the researchers concluded.

Researchers reported updated results from a phase I trial of donor-derived CD7 chimeric antigen receptor (CAR) T cells for relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). The results were presented at the 2022 American Society of Clinical Oncology Annual Meeting.This study, conducted by Jing Pan and colleagues, was comprised of 20 patients with prior stem cell transplantation (SCT). The population of interest all received CAR T cells from prior SCT donors, while patients without SCT history received CAR T cells from new donors who provided stem cells CAR T therapy, the researchers noted. The primary outcome of interest in this analysis was safety with efficacy secondary.According to the results, 95% of patients responded and were followed for over 15 months. The short-term adverse events reported included grade 3 or higher cytokine release syndrome (10%) and grade 1-2 graft-versus-host disease (GVHD, 60%), which were all reversible, the researchers wrote. The objective response and complete remission rate were 95% and 85% following day 30 post-infusion, with one-year progressive-free survival (PFS) and overall survival (OS) rates observed at 51.6% (95% CI, 24.7-78.4%) and 72.5% (95% CI, 51.9-93.0%), respectively].“Donor-derived CD7 CAR T cell therapy showed encouraging activity in treating r/r T-ALL. Relapse emerges as major issues impeding long-term outcomes. CD7-negative relapse was commonly observed under CAR T cell surveillance. Late onset GVHD and infections may occur and should be carefully managed,” the researchers concluded.

Jordana Jampel

Comparing Diets for IBS Relief: Mediterranean Versus Low-FODMAP

Gastroenterology

Anne Marie Morse, DO

Wearable Sleep Tech: Promise, Pitfalls, and Personalization

Sleep Disorders

Alexa Steckler

Improving Fertility Counseling for Young Patients With Cancer: A National Survey

Breast Cancer News

Latest News

Updated Data on a Phase I Trial of Donor-Derived CD7 CAR T Cells for T-cell Acute Lymphoblastic Leukemia

ASCO 2022

Researchers reported updated results from a phase I trial of donor-derived CD7 chimeric antigen receptor (CAR) T cells for relapsed or refractory T-cell acute lymphoblastic ...

Updated Data on a Phase I Trial of Donor-Derived CD7 CAR T Cells for T-cell Acute Lymphoblastic

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe